secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001140361-24-000832
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore strategic update: KIMMTRAK expansion, PRAME Phase 3 start, new autoimmune candidates
--------------------------------------------------------------------------------

- Preliminary cash and cash equivalents ~$443M as of Dec 31, 2023.
- KIMMTRAK expansion: TEBE-AM (2L+ cutaneous melanoma) Phase 2 data Q4 2024; ATOM (adjuvant uveal melanoma) Phase 3 start 2H 2024.
- PRAME franchise: PRISM-MEL-301 Phase 3 in 1L cutaneous melanoma to begin randomization Q1 2024; Phase 1/2 data across melanoma, ovarian, NSCLC expected in 2024.
- New candidates: IMC-R117C (PIWIL1) for GI cancers; two autoimmune candidates for type 1 diabetes and dermatology.
- HIV candidate IMC-M113V Phase 1 MAD data expected 2H 2024; HBV trial amended to include HCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124000832/0001140361-24-000832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124000832/ef20018111_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-000832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer